Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder.
dorsolateral prefrontal cortex
fMRI
kynurenine
major depressive disorder
metabolomics
Journal
Psychiatry and clinical neurosciences
ISSN: 1440-1819
Titre abrégé: Psychiatry Clin Neurosci
Pays: Australia
ID NLM: 9513551
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
16
03
2022
received:
26
11
2021
accepted:
24
04
2022
pubmed:
12
5
2022
medline:
12
8
2022
entrez:
11
5
2022
Statut:
ppublish
Résumé
To establish treatment response biomarkers that reflect the pathophysiology of depression, it is important to use an integrated set of features. This study aimed to determine the relationship between regional brain activity at rest and blood metabolites related to treatment response to escitalopram to identify the characteristics of depression that respond to treatment. Blood metabolite levels and resting-state brain activity were measured in patients with moderate to severe depression (n = 65) before and after 6-8 weeks of treatment with escitalopram, and these were compared between Responders and Nonresponders to treatment. We then examined the relationship between blood metabolites and brain activity related to treatment responsiveness in patients and healthy controls (n = 36). Thirty-two patients (49.2%) showed a clinical response (>50% reduction in the Hamilton Rating Scale for Depression score) and were classified as Responders, and the remaining 33 patients were classified as Nonresponders. The pretreatment fractional amplitude of low-frequency fluctuation (fALFF) value of the left dorsolateral prefrontal cortex (DLPFC) and plasma kynurenine levels were lower in Responders, and the rate of increase of both after treatment was correlated with an improvement in symptoms. Moreover, the fALFF value of the left DLPFC was significantly correlated with plasma kynurenine levels in pretreatment patients with depression and healthy controls. Decreased resting-state regional activity of the left DLPFC and decreased plasma kynurenine levels may predict treatment response to escitalopram, suggesting that it may be involved in the pathophysiology of major depressive disorder in response to escitalopram treatment.
Identifiants
pubmed: 35543406
doi: 10.1111/pcn.13373
pmc: PMC9544423
doi:
Substances chimiques
Kynurenine
343-65-7
Escitalopram
4O4S742ANY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-376Subventions
Organisme : AMED
ID : JP20pc0101061
Organisme : AMED
ID : JP18dk0307076
Organisme : AMED
ID : JP18dm0307008
Organisme : AMED
ID : JP18dm0307002
Informations de copyright
© 2022 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.
Références
Brain Behav Immun. 2020 Jul;87:404-412
pubmed: 31978524
Biol Psychiatry. 2000 Oct 15;48(8):830-43
pubmed: 11063978
J Clin Psychiatry. 2012 Apr;73(4):451-9
pubmed: 21903032
Science. 2000 Jun 9;288(5472):1835-8
pubmed: 10846167
Psychiatry Res. 2013 Dec 30;214(3):296-305
pubmed: 24446548
J Affect Disord. 2012 Jun;139(1):56-65
pubmed: 22425432
Neuron. 2013 Feb 20;77(4):736-49
pubmed: 23439125
Psychiatry Clin Neurosci. 2006 Jun;60(3):332-9
pubmed: 16732750
Neurosci Biobehav Rev. 2018 Jul;90:16-25
pubmed: 29608993
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Clin Pharmacol Ther. 2011 Jan;89(1):97-104
pubmed: 21107318
J Neurosci. 2020 Feb 12;40(7):1527-1537
pubmed: 31911457
Neuropsychobiology. 2003;47(1):21-6
pubmed: 12606841
Psychoneuroendocrinology. 2019 Mar;101:72-79
pubmed: 30419374
Can J Psychiatry. 2016 Sep;61(9):540-60
pubmed: 27486148
J Neurochem. 2002 Jul;82(2):258-68
pubmed: 12124427
Neuropsychopharmacology. 2020 May;45(6):998-1007
pubmed: 31940661
Neuroimage. 2014 Feb 15;87:345-55
pubmed: 24220041
Am J Physiol Cell Physiol. 2020 May 1;318(5):C818-C830
pubmed: 32208989
Mol Psychiatry. 2013 Nov;18(11):1199-204
pubmed: 23337947
J Neurosci Methods. 2008 Jul 15;172(1):137-41
pubmed: 18501969
Neuroimage. 2018 Feb 15;167:104-120
pubmed: 29155184
Mol Psychiatry. 2021 Aug;26(8):4158-4178
pubmed: 33230205
Neuroimage Clin. 2017 Jul 18;16:116-124
pubmed: 28794972
PLoS One. 2013 Jul 17;8(7):e68283
pubmed: 23874572
Neuropsychobiology. 2016;74(2):69-77
pubmed: 28052303
Trends Cogn Sci. 2005 May;9(5):242-9
pubmed: 15866151
Nat Rev Mol Cell Biol. 2004 Sep;5(9):763-9
pubmed: 15340383
Trends Cogn Sci. 2011 Oct;15(10):483-506
pubmed: 21908230
Cereb Cortex. 2014 Nov;24(11):2981-90
pubmed: 23765157
Neuroscience. 2018 Jul 1;382:80-92
pubmed: 29723574
Hum Brain Mapp. 2008 Aug;29(8):958-72
pubmed: 17636563
Front Psychol. 2017 Oct 04;8:1561
pubmed: 29046648
Behav Brain Res. 2015 Mar 15;281:339-47
pubmed: 25513974
Neuroimage. 2017 Nov 1;161:149-170
pubmed: 28826946
Front Hum Neurosci. 2021 Mar 17;15:620342
pubmed: 33815078
Brain Behav Immun. 2019 Jan;75:155-162
pubmed: 30675874
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
pubmed: 6080235
J Neurosci. 2015 Mar 4;35(9):3966-77
pubmed: 25740525
Front Hum Neurosci. 2019 May 28;13:164
pubmed: 31191274
Sci Rep. 2017 Jul 7;7(1):4855
pubmed: 28687801
Biol Psychiatry. 2001 Aug 1;50(3):171-8
pubmed: 11513815
J Affect Disord. 2009 Jan;112(1-3):206-11
pubmed: 18559283
J Psychiatry Neurosci. 2009 Mar;34(2):119-26
pubmed: 19270762
Neuroimage. 2014 Dec;103:249-257
pubmed: 25251869
Biol Psychiatry. 2007 Dec 1;62(11):1236-43
pubmed: 17601497
Psychiatry Clin Neurosci. 2005 Oct;59(5):517-26
pubmed: 16194252
Am J Psychiatry. 2001 Jun;158(6):899-905
pubmed: 11384897
Brain Connect. 2012;2(3):125-41
pubmed: 22642651
J Neural Transm (Vienna). 2012 Feb;119(2):235-43
pubmed: 21660485
Hum Brain Mapp. 2008 Jun;29(6):683-95
pubmed: 17598168
J Neurochem. 1978 Mar;30(3):607-13
pubmed: 681935
Neuroimage. 2017 Apr 1;149:220-232
pubmed: 28161310
Behav Brain Res. 2016 Feb 1;298(Pt B):301-9
pubmed: 26519557
Drug Discov Today. 2014 May;19(5):539-61
pubmed: 24561326
Neurochem Res. 1980 Mar;5(3):223-39
pubmed: 6154900
Br J Pharmacol. 2013 Jul;169(6):1211-27
pubmed: 23647169
J Neurosci. 2020 Mar 18;40(12):2458-2470
pubmed: 32051326
Neuroimage. 2010 Jan 15;49(2):1432-45
pubmed: 19782143
Neuropsychologia. 1971 Mar;9(1):97-113
pubmed: 5146491
Neurosci Biobehav Rev. 2018 Sep;92:477-485
pubmed: 29940237
Neurosci Biobehav Rev. 2014 Sep;45:100-18
pubmed: 24875392
Neuropsychopharmacology. 2009 Jan;34(1):173-86
pubmed: 18843269
Transl Psychiatry. 2016 Apr 26;6:e789
pubmed: 27115120
Curr Neurovasc Res. 2005 Jul;2(3):249-60
pubmed: 16181118
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
J Affect Disord. 2020 Jan 1;260:490-497
pubmed: 31539685
J Neurochem. 1991 Jun;56(6):2007-17
pubmed: 1827495
Ann N Y Acad Sci. 2012 Mar;1251:E1-24
pubmed: 23025352
J Affect Disord. 2013 Dec;151(3):1097-101
pubmed: 24074717
Hum Brain Mapp. 2016 Jun;37(6):2151-60
pubmed: 26955899
Nat Rev Drug Discov. 2013 Jan;12(1):64-82
pubmed: 23237916
Transl Psychiatry. 2011;1:
pubmed: 22162828
Transl Psychiatry. 2016 Mar 08;6:e754
pubmed: 26954981
Psychiatry Clin Neurosci. 2009 Jun;63(3):423-5
pubmed: 19566776
Sci Rep. 2020 Oct 8;10(1):16822
pubmed: 33033336
Front Neurosci. 2015 Oct 27;9:395
pubmed: 26578859
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun;26(5):945-54
pubmed: 12369271
Transl Psychiatry. 2020 Oct 19;10(1):353
pubmed: 33077728
Behav Neurosci. 2020 Aug;134(4):323-331
pubmed: 32658524
Behav Brain Res. 2009 Aug 12;201(2):239-43
pubmed: 19428640
Ren Fail. 2013;35(5):648-53
pubmed: 23650931
Neurosci Biobehav Rev. 2016 Feb;61:53-65
pubmed: 26562681